ABIOMED INC ABIOMED ORD SHS 

$381,02
38
+$0,00+0%Kamis 16.24

Statistik

Tertinggi hari ini
-
Terendah hari ini
-
Tertinggi 52M
-
Terendah 52M
-
Volume
-
Vol. rata2
-
Kap. pasar
0
Rasio P/E
1,28
Imbal hasil dividen
-
Dividen
-

Laporan keuangan

30 OktDiperkirakan
Q1 2022
Q2 2022
Q3 2022
Q4 2022
Q1 2023
Q2 2023
Q3 2023
1,19
1,57
1,94
2,32
EPS yang diharapkan
N/A
EPS aktual
N/A

Keuangan

13,23%Margin laba
Menguntungkan
2016
2017
2018
2019
2020
2021
1,03BPendapatan
136,51MLaba bersih

Pesaing

Daftar ini adalah analisis berdasarkan peristiwa pasar terbaru. Ini bukan rekomendasi investasi.

Tentang

Abiomed, Inc. engages in the research, development, and sale of medical devices to assist or replace the pumping function of the failing heart. It also provides a continuum of care to heart failure patients. The company offers Impella 2.5, a percutaneous micro heart pump with integrated motor and sensors; and Impella CP, a device for use by interventional cardiologists to support patients in the cath lab, as well as by cardiac surgeons in the heart surgery suite. It also provides Impella 5.0, Impella LD, and Impella 5.5, which are percutaneous micro heart pumps with integrated motors and sensors for use primarily in the heart surgery suite; Impella RP, a percutaneous catheter-based axial flow pump; Impella SmartAssist platform that includes optical sensor technology for improved pump positioning and the use of algorithms that enable improved native heart assessment during the weaning process; Impella Connect, a cloud-based technology that enables secure and remote viewing of the automated impella controller for physicians and hospital staffs; and OXY-1 System, a portable external respiratory assistance device. In addition, the company is developing Impella ECP, a pump for blood flow of greater than three liters per minute; Impella XR Sheath, a sheath that expands and recoils allowing small bore access and closure with Impella heart pumps; Impella BTR, a percutaneous micro heart pump with integrated motors and sensors; and preCARDIA, a catheter-mounted superior vena cava therapy system designed to rapidly treat acutely decompensated heart failure. Abiomed, Inc. sells its products through direct sales and clinical support personnel in the Germany, France, United States, Japan, Europe, Canada, Latin America, the Asia-Pacific, and the Middle East. The company was founded in 1981 and is headquartered in Danvers, Massachusetts.
Tampilkan lebih banyak
CEO
Mr. Michael R. Minogue
Karyawan
2003
Negara
Amerika Serikat
ISIN
US0036541003
WKN
000873886

Pencatatan

0 Komentar

Bagikan pendapatmu

FAQ

Berapa harga saham ABIOMED INC ABIOMED ORD SHS hari ini?▼
Harga saat ini dari 0H7S.LSE adalah $381,02 USD — naik sebesar +0% dalam 24 jam terakhir. Pantau kinerja harga saham ABIOMED INC ABIOMED ORD SHS lebih dekat di grafik.
Apa simbol saham ABIOMED INC ABIOMED ORD SHS?▼
Tergantung pada bursa, simbol saham dapat berbeda. Misalnya, di bursa London Exchange, saham ABIOMED INC ABIOMED ORD SHS diperdagangkan dengan simbol 0H7S.LSE.
Berapa pendapatan ABIOMED INC ABIOMED ORD SHS tahun lalu?▼
Pendapatan ABIOMED INC ABIOMED ORD SHS tahun lalu berjumlah 1,03B USD.
Berapa pendapatan bersih ABIOMED INC ABIOMED ORD SHS tahun lalu?▼
Pendapatan bersih 0H7S.LSE untuk tahun lalu adalah 136,51M USD.
Berapa jumlah karyawan ABIOMED INC ABIOMED ORD SHS?▼
Per 26 Oktober 2026, perusahaan memiliki 2.003 karyawan.
ABIOMED INC ABIOMED ORD SHS berada di sektor apa?▼
ABIOMED INC ABIOMED ORD SHS beroperasi di sektor Lainnya.
Kapan ABIOMED INC ABIOMED ORD SHS menyelesaikan split saham?▼
ABIOMED INC ABIOMED ORD SHS belum melakukan split saham baru-baru ini.
Di mana kantor pusat ABIOMED INC ABIOMED ORD SHS?▼
Kantor pusat ABIOMED INC ABIOMED ORD SHS berlokasi di Danvers, Amerika Serikat.